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Abstract
Objective. The ACT-MOVE study assessed the real-world efficacy and safety of s.c. tocilizumab (TCZ-
SC), provided as monotherapy or in combination with conventional synthetic DMARDs (csDMARDs) over
1year, in patients with RA and an inadequate response to csDMARD therapy and/or first TNF inhibitor.
Methods. In this UK multicentre, open-label phase IIIb study, patients received TCZ-SC 162mg once
weekly for 52weeks as monotherapy or with csDMARDs. Efficacy and safety were evaluated at base-
line, weeks 2 and 4 and every 4weeks thereafter up to week 52.
Results. Of 161 patients who received at least one dose of TCZ-SC, 21 (13.0%) received TCZ-SC
alone and 140 (87.0%) TCZ-SC with a csDMARD(s). From baseline to week 52, there was a mean de-
crease in DAS28-ESR score among all patients (!3.68), and within monotherapy (!3.75) and combina-
tion therapy (!3.67) groups. The proportion of patients who achieved DAS28 clinical remission
(DAS28-ESR <2.6) at week 52 was 75.4% (95% CI 66.8, 82.8). At the same time point, "80% of
patients who remained on TCZ-SC achieved DAS28 clinical remission or had low disease activity
(DAS28-ESR "2.6 and #3.2). Overall, 6.2% of patients had at least one serious adverse event (10.2/
100 patient-years), and there was one death; 11.2% of patients discontinued owing to adverse events.
Conclusion. TCZ-SC was effective and tolerated in a real-world setting over 1 year. The efficacy of
TCZ-SC was similar whether given as monotherapy or with csDMARDs; its safety profile was consis-
tent with that previously established.
Trial registration. ClinicalTrials.gov, http://www.clinicaltrials.gov, NCT02046603.
Key words: rheumatoid arthritis, tocilizumab, conventional synthetic DMARDs, subcutaneous, biological ther-
apies, real world, United Kingdom
Key messages
. 75% of ‘real-world’ RA patients failing conventional synthetic DMARDs/first TNF inhibitor achieve remission
with s.c. tocilizumab.
. The efficacy of s.c. tocilizumab in RA was similar as monotherapy or combined with conventional synthetic DMARDs.
. The real-world safety profile of s.c. tocilizumab in RA was consistent with that previously established.
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Introduction
RA is an autoimmune disease affecting $1% of the
global population that is associated with painful inflam-
mation and destruction of the joints and surrounding tis-
sue [1]. In Europe, recommended treatment involves early
initiation of conventional synthetic DMARDs (csDMARDs)
and, if an adequate response is not achieved, addition of
a biological therapy, such as tocilizumab (TCZ), abata-
cept or a TNF inhibitor, or a targeted synthetic DMARD
(i.e. a Janus kinase inhibitor) [2].
TCZ is a recombinant, humanized, monoclonal anti-
body targeting soluble and membrane-bound IL-6 recep-
tors. IL-6 is a pro-inflammatory cytokine with a role in
several inflammatory diseases, including RA [3, 4]. TCZ
was initially approved as an i.v. formulation (TCZ-IV) for
treatment of patients with moderate-to-severe active RA
and an inadequate response or intolerance to previous
csDMARDs or anti-TNF therapy. Data from several
phase III trials demonstrated the efficacy and safety of
TCZ-IV alone and with csDMARD therapy in this patient
population [5–9]. Longer-term data from the LITHE trial
also showed that the efficacy and safety of TCZ-IV were
maintained for up to 5 years [10].
An s.c. formulation of TCZ (TCZ-SC) was later devel-
oped and approved [11, 12]. Many RA patients express a
preference for s.c. administration, preferring the conve-
nience of home self-administration with ready-to-use pre-
filled syringes [13]. The efficacy and safety of TCZ-SC as
monotherapy or in combination with csDMARD therapy
was evaluated in three phase III studies in patients with
RA and an inadequate response to csDMARDs [14–16].
Data from the SUMMACTA study showed non-inferiority
of TCZ-SC (162mg weekly) to TCZ-IV (8mg/kg every
4weeks), both in combination with csDMARDs, with re-
gard to the proportion of patients achieving an ACR 20%
improvement (ACR20) response at week 24 [14]. In the
BREVACTA study, ACR20 at 24weeks with TCZ-SC
(162mg every 2weeks) plus csDMARDs was superior to
s.c. placebo with csDMARDs [15]. In the MUSASHI
study, TCZ-SC monotherapy (162mg every 2weeks) was
shown to be non-inferior to TCZ-IV monotherapy (8mg/
kg every 4weeks) with respect to ACR20 at week 24
[16]. In all these studies, TCZ-SC was well tolerated, with
a safety profile consistent with TCZ-IV [14–16]. Long-term
extension studies with TCZ-SC, ranging from 84 to 108
weeks’ duration, showed durable efficacy and mainte-
nance of a favourable safety profile [17–19].
Recently, ‘real-world’ use of TCZ-SC has been evalu-
ated prospectively, with the intention of providing more
information about outcomes when treatment is adminis-
tered at home. TOZURA is a multinational, open-label,
phase IV study programme designed to evaluate the
efficacy and safety of TCZ-SC as monotherapy and in
combination with csDMARD(s) in adult patients with mod-
erate-to-severe RA across a broad geographical setting.
Using a common design framework, the programme com-
prises 11 studies in 22 countries [20]. Recently published
data from the overall TOZURA programme confirmed the
existing efficacy and safety profiles of TCZ-SC, showing
comparable results when it was used alone or in combi-
nation over 24weeks [20].
The UK-based ACT-MOVE study was part of the
TOZURA programme and was designed to assess the
real-world efficacy of TCZ-SC, as monotherapy or in
combination with csDMARD therapy, for up to 1 year in
RA patients with an inadequate response to csDMARDs
and/or first TNF inhibitor.
Methods
Patients
The study population included TCZ-naı¨ve adults
("18years old) with active RA, according to the revised
1987 ACR criteria or 2010 EULAR/ACR criteria, and an
inadequate response to current csDMARD therapy or first
TNF inhibitor. Past TNF inhibitors may have been given
as monotherapy or in combination with MTX or another
csDMARD. An inadequate response to anti-TNF treat-
ment was defined as a DAS using 28 joints (DAS28) im-
provement of <1.2, or patients not achieving a DAS28 of
#3.2 according to a treat-to-target strategy. Inadequate
response to csDMARD therapy was assessed according
to local guidelines.
Key exclusion criteria included major surgery #8weeks
before screening or planned major surgery #6months af-
ter baseline, on-going rheumatic autoimmune disease
other than RA, functional class IV status, prior history
of or current inflammatory joint disease other than RA,
treatment with any investigational agent #4weeks or #5
half-lives of the investigational agent before screening
(whichever was longer), IA or parenteral glucocorticoids
or immunization with a live/attenuated vaccine #4weeks
before screening, treatment with any cell-depleting thera-
pies or alkylating agents, and treatment with i.v. c-globu-
lin or plasmapheresis #6months before baseline.
Patients were also excluded if they had evidence of seri-
ous uncontrolled concomitant disease, a history of diver-
ticulitis or symptomatic lower gastrointestinal (GI)
conditions that might predispose to perforation, any ac-
tive infections, positive hepatitis B surface antigen or
hepatitis C antibody, history of or currently active malig-
nancy, or serious allergies to biological agents. Complete
eligibility criteria are provided in supplementary Table S1,
available at Rheumatology Advances in Practice online.
Final protocols, amendments and informed consent
documentation were approved by the local institutional
review boards or independent ethics committees of the
study centres. All patients provided written, informed
consent, according to the Declaration of Helsinki.
Study design
ACT-MOVE (NCT02046603) was a real-world, multi-
centre, open-label, single-arm, phase IIIb trial performed
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between March 2014 and August 2016. Patients re-
ceived TCZ 162mg once a week for 52weeks, adminis-
tered by s.c. injection as a single, fixed dose
irrespective of body weight. Each TCZ dose was sup-
plied in a 1-ml, ready-to-use, single-use, prefilled sy-
ringe. Concomitant treatment with csDMARDs, including
AZA, chloroquine, HCQ, LEF, MTX or SSZ, was permit-
ted if the patient had maintained a stable dose for
"4weeks before baseline assessment. Concomitant
csDMARDs could be used alone or in combination, ex-
cept for the combination of MTX and LEF. Oral NSAIDs
and glucocorticoids (#10mg/day prednisone or equiva-
lent) were permitted if patients maintained a stable dose
for "4weeks before baseline.
After administration of the first s.c. injection under
close investigator supervision, patients or caregivers
could administer subsequent doses of TCZ-SC at home.
Recommended injection sites were the front of the mid-
dle thighs and the lower part of the abdomen below the
navel, except for the two-inch area directly around the
navel. The outer area of the upper arms could also be
used by caregivers administering an injection.
Objectives and assessments
The primary study objective was to assess the efficacy
of TCZ-SC (as monotherapy or in combination) in
patients with an inadequate response to csDMARDs
and/or first TNF inhibitor. Secondary objectives included
evaluating TCZ-SC safety and tolerability, efficacy over
time, the proportion of patients who achieved low dis-
ease activity, the proportion of patients who achieved
remission, and adherence to MTX (in patients prescribed
MTX in combination with TCZ-SC).
Efficacy and safety were evaluated at baseline, weeks
2 and 4 and every 4weeks thereafter up to week 52, un-
less specified otherwise, with an additional follow-up
safety evaluation performed 8weeks after study comple-
tion. Efficacy assessments included change in DAS28 us-
ing ESR, change in clinical disease activity index (CDAI),
change in simplified disease activity index (SDAI), ACR
response scores, EULAR response, change in total swol-
len joint count of 28 joints and change in total tender joint
count of 28 joints. Changes in serum CRP and ESR were
also assessed. Patient-reported outcome assessments
comprised global assessment of disease activity visual
analog scale, RA-related pain visual analog scale, HAQ-
disability index, functional assessment of chronic illness
therapy – fatigue, and an MTX adherence questionnaire.
The MTX adherence questionnaire, developed for this
study, asked MTX-prescribed patients, ‘Over the last
3months you were prescribed 12 doses of MTX, how
many (approximately) have you taken?’.
Safety assessments included monitoring of adverse
events [AEs; e.g. incidence and severity of treatment-
emergent adverse events (TEAEs), incidence of
treatment-emergent serious adverse events (TESAEs),
TEAEs leading to study withdrawal or dose modification
and TEAEs of special interest]. The TEAEs of special in-
terest were identified via standardized Medical Dictionary
for Regulatory Activities (MedDRA) query and included
serious infections, GI perforations, demyelinating disor-
ders, haematological abnormalities and bleeding events,
hepatic enzyme elevation, cardiovascular disease and el-
evated lipids, malignancies, local injection site reactions
and anaphylaxis/hypersensitivity reactions. Other safety
variables included standard laboratory parameters, physi-
cal examination findings and vital signs. Samples for anti-
drug antibody (ADA) testing were collected at baseline,
weeks 12 and 24, at completion or early withdrawal visit
and at the follow-up visit 8weeks after the final dose.
Statistical analyses
Study analyses were exploratory and primarily descrip-
tive. No hypothesis testing was performed. A sample
size of 160 patients was planned. Assuming an S.D. of
1.4 DAS28-ESR units and 13 CDAI units, respectively,
the expected precision of the estimate, as measured by
the 95% CI around the mean change from baseline, was
0.43 for DAS28-ESR and 4.0 for CDAI. For 80% power,
the detectable change in the two variables, using a
t-test at the 5% significance level, was 0.31 units for
DAS28-ESR and 2.90 units for CDAI.
The proportion of patients who achieved DAS28 re-
mission (DAS28-ESR <2.6) at weeks 24 and 52 was cal-
culated along with 95% Clopper–Pearson CIs. Safety
event incidence rates per 100 patient-years (PY) of
TCZ-SC exposure were estimated using the Poisson
distribution. The Clopper–Pearson method was used to
calculate 95% CI for the incidence of TEAEs of special
interest. Descriptive statistical methods were used to
evaluate all other efficacy end-points and safety param-
eters. All reported analyses were performed in the full
analysis set (FAS), which included all enrolled patients
who received at least one dose of TCZ-SC.
Results
Patient disposition and baseline characteristics
Overall, 162 patients were enrolled across 38 UK
centres; 131 and 31 patients had experienced an inade-
quate response to current csDMARD therapy or first
TNF inhibitor, respectively. The FAS included 161
patients, because one patient in the monotherapy group
did not receive TCZ-SC. Twenty-one FAS patients
(13.0%) received TCZ-SC monotherapy, and 140 FAS
patients (87.0%) received TCZ-SC in combination with
csDMARDs. During the 52-week study, five patients
(23.8%) discontinued from monotherapy and 33 patients
(23.6%) from combination therapy; AEs were the most
common reason for withdrawal (supplementary Fig. S1,
available at Rheumatology Advances in Practice online).
Patient demographics and disease characteristics at
baseline are shown in Table 1. The mean baseline DAS28-
ESR score for all patients was 5.53. Demographics were
generally comparable between monotherapy and combina-
tion therapy groups. However, glucocorticoid use was
higher in the monotherapy group than in the combination
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group (33.3 and 21.4% of patients, respectively); in addi-
tion, more patients in the monotherapy group had received
prior anti-TNF treatment (42.8 and 15.7%, respectively).
Efficacy
There were mean decreases from baseline in DAS28-
ESR scores at all time points (Fig. 1A). From baseline to
week 52, the mean change in DAS28-ESR score for all
patients was !3.68 (!3.75 and !3.67 in the monother-
apy and combination groups, respectively). The propor-
tion of all patients achieving DAS28 clinical remission
(DAS28-ESR <2.6) was 66.2% (95% CI 57.6, 74.1) at
week 24 and 75.4% (95% CI 66.8, 82.8) at week 52.
The proportion of patients achieving DAS28 clinical re-
mission at week 52 was >70% in both the monotherapy
and combination groups (Fig. 2). At week 52, "80% of
patients remaining on TCZ-SC therapy were assessed
as achieving DAS28 clinical remission or having low dis-
ease activity (DAS28-ESR "2.6 and #3.2; Fig. 2).
At all time points, there was a mean decrease from
baseline in CDAI scores (Fig. 1B). From baseline to
week 52, the mean change in CDAI score was !24.55
(!25.48 and !24.42 in the monotherapy and combina-
tion groups, respectively). At week 52, the proportion of
patients who achieved CDAI clinical remission (CDAI
#2.8) was 29.8% in all patients and 28.6 and 30.0% in
the monotherapy and combination groups, respectively
(Fig. 2). The proportion of patients falling into other CDAI
categories at week 52 was as follows: low disease activ-
ity (CDAI >2.8 to #10.0): 29.2, 38.1 and 27.9%; moder-
ate disease activity (CDAI >10.0 to #22.0): 13.7, 9.5
and 14.3%; and high disease activity (CDAI >22.0): 3.7,
0.0 and 4.3% (Fig. 2). At all time points, there was a
mean decrease from baseline in SDAI scores for all
patients and in both groups (Fig. 1C). SDAI disease ac-
tivity data at week 52 were similar to CDAI data (Fig. 2).
The proportion of all patients achieving ACR20,
ACR50 and ACR70 responses increased over time
(week 2 vs week 52: ACR20, 18.0 vs 62.1%; ACR50, 3.1
vs 50.3%; ACR70, 0.0 vs 37.9%). At week 52, 38.1% of
patients in the monotherapy group and 52.1% in the
combination group had achieved an ACR50 response
(Fig. 3). The proportion of patients with a good EULAR
response increased over time (19.9% at week 2 vs
63.4% at week 52 for all patients). At week 52, 57.1%
of patients in the monotherapy group and 64.3% in the
combination group achieved a good EULAR response
(Fig. 3). There were decreases in swollen joint count of
28 joints and tender joint count of 28 joints of >75%
from baseline to week 52 for all patients and in both
groups (supplementary Tables S2 and S3, available at
Rheumatology Advances in Practice online). Serum con-
centrations of CRP and ESR decreased at all time points
(supplementary Figs S2 and S3, available at
Rheumatology Advances in Practice online).
For patient-reported outcome assessments, visual an-
alog scale scores decreased for patient global assess-
ment of disease activity and for RA-related pain at all
time points (Fig. 4A and B). Mean baseline to week 52
changes for all patients, monotherapy and combination,
respectively, were !40.8, !44.9 and !40.2 for disease
activity, and !36.5, !33.4 and !36.9 for RA-related
pain. There were decreases in HAQ-disability index
scores from baseline to week 52 in all patients and both
groups, indicating an improvement in disability (mean
baseline to week 52 changes were !0.56, !0.47 and
!0.57 for all patients, monotherapy and combination,
TABLE 1 Baseline patient demographics and disease characteristics (full analysis set)
Characteristic TCZ-SC monotherapy
(n5 21)
TCZ-SC1 csDMARD
(n5 140)
Total population
(n5 161)
Age, mean (range), years 53.9 (27–79) 55.3 (32–81) 55.1 (27–81)
Female, n (%) 16 (76.2) 104 (74.3) 120 (74.5)
Race, n (%)
White 20 (95.2) 135 (96.4) 155 (96.3)
Other 1 (4.8) 5 (3.6) 6 (3.7)
CRP, mean (S.D.), mg/l 15.4 (19.7) 16.1 (25.5) 16.0 (24.8)
RF-positive, n (%) 10 (47.6) 90 (64.3) 100 (62.1)
Anti-CCP2-positive, n (%) 12 (57.1) 101 (72.1) 113 (70.2)
Disease activity, mean (S.D.)
DAS28-ESR 5.52 (1.01) 5.53 (1.26) 5.53 (1.23)
CDAI 29.69 (11.209) 30.88 (10.953) 30.73 (10.959)
SDAI 31.23 (11.892) 32.33 (11.620) 32.19 (11.624)
HAQ-DI 1.81 (0.56) 1.74 (0.64) 1.75 (0.63)
Concomitant RA medications, n (%)
MTX 0 (0) 43 (30.7)a 43 (26.7)
Glucocorticoids 7 (33.3) 30 (21.4) 37 (23.0)
Prior anti-TNF treatment for RA, n (%) 9 (42.8) 22 (15.7) 31 (19.3)
aData shown are baseline data; csDMARDs could be added after baseline in this group. CDAI: clinical disease activity in-
dex; csDMARD: conventional synthetic DMARD; DAS28: DAS for 28 joints; DI: disability index; SDAI: simplified disease ac-
tivity index; TCZ-SC: tocilizumab s.c.
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FIG. 1 Mean DAS28-ESR (A), clinical disease activity index (B) and simplified disease activity index (C) scores over
52weeks (full analysis set)
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respectively; Fig. 4C). The functional assessment of
chronic illness therapy – fatigue score increased at all
time points, indicating a decrease in fatigue (mean base-
line to week 52 changes were 13.8, 16.9 and 13.3 for all
patients, monotherapy and combination, respectively;
Fig. 4D).
Of the 140 patients who received TCZ in combination
with csDMARDs, 100 (71.4%) had previously been, or
were currently, receiving MTX [although at baseline,
MTX was listed as a concomitant RA medication in only
43 patients (30.7%; Table 1)]. Among the aforemen-
tioned 100 patients, 97 completed the MTX adherence
questionnaire at baseline. The number of patients com-
pleting this questionnaire at weeks 12, 24, 36 and 52
was 80, 65, 60 and 60, respectively. Mean adherence to
MTX in patients completing the questionnaire was
>90% at all time points.
Safety
Total mean TCZ-SC exposure was 321.6 and 310.4 days
in the monotherapy and combination groups, respec-
tively. A total of 157 patients (97.5%) had at least one
TEAE, with a similar proportion of patients affected in
the monotherapy and combination groups (95.2 vs
97.9%, respectively). The TEAE rate per 100 PY was
966.1 for all patients but was higher in the combination
group than in the monotherapy group (997.7 vs 762.6).
Most TEAEs were mild to moderate in severity (Table 2).
One patient had a TEAE that was considered life-
FIG. 2 DAS28-ESR, clinical disease activity index and simplified disease activity index disease activity at week 52 (full
analysis set)
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FIG. 3 ACR and EULAR responses at week 52 (full analysis set)
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FIG. 4 Mean change in select patient-reported outcome assessment scores over time (weeks 1–52; full analysis set)
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threatening (atrial fibrillation) and one patient died (pul-
monary fibrosis); both patients were in the combination
group.
The most common class of TEAEs was infections,
reported by 70.2% of all patients (76.2 and 69.3% in the
monotherapy and combination groups, respectively).
Nasopharyngitis was the most frequently reported indi-
vidual TEAE (23.6% of all patients; supplementary Table
S4, available at Rheumatology Advances in Practice on-
line). TEAEs resulting from injection site reactions were
experienced by 34 (21.1%) patients [four (19.0%) and 30
(21.4%) in the monotherapy and combination groups,
respectively]. No patient had a GI perforation.
TEAEs considered by the investigator to be related to
study medication were reported in 112 patients (69.6%);
the proportion of patients with these events was higher in
the combination group than in the monotherapy group
(Table 2). Fourteen TESAEs were reported in 10 patients
(6.2%; supplementary Table S5, available at Rheumatology
Advances in Practice online), with a rate of 10.2 per 100
PY; four patients (2.5%) experienced a serious infection
(3.6 per 100 PY; Table 2). Eighteen patients (11.2%)
discontinued study treatment owing to TEAEs; rates of dis-
continuation in the monotherapy and combination groups
were broadly similar (Table 2). The most common classes
of TEAEs causing withdrawal were infections (n¼ 4) and GI
disorders, abnormal laboratory investigations and skin/s.c.
tissue disorders (n¼ 3 each). Nineteen patients (11.8%;
three in the monotherapy group and 16 in the combination
group) experienced a total of 25 TEAEs that led to TCZ-SC
dose modification (dosing interrupted and/or dose fre-
quency reduced).
Seventy patients (43.5%; 95% CI 35.7, 51.5) had a
TEAE of special interest (Table 2). TEAEs of special inter-
est that occurred in "3% of patients in any group are
shown in supplementary Table S6 (available at
Rheumatology Advances in Practice online); the most
common were rash, injection site bruising and contusion.
At week 24, 2 of 135 patients (1.2%) had an ADA-
positive result; both patients were in the combination
group, and one had neutralizing antibodies to TCZ-SC.
Samples were collected from 24 patients at the 8-week
follow-up visit; none was ADA positive at this time
point.
TABLE 2 Summary of treatment-emergent adverse events (full analysis set)a
Events TCZ-SC monotherapy
(n5 21)
TCZ-SC1 csDMARD
(n5 140)
Total population
(n5 161)
TEAEs
Total number of TEAEs 141 1187 1328
Patients with at least one TEAE, n (%) 20 (95.2) 137 (97.9) 157 (97.5)
Most extreme TEAE intensity, n (%)
Mild 6 (28.6) 48 (34.3) 54 (33.5)
Moderate 8 (38.1) 66 (47.1) 74 (46.0)
Severe 6 (28.6) 21 (15.0) 27 (16.8)
Life-threatening 0 (0.0) 1 (0.7) 1 (0.6)
Rate, per 100 PY of exposure 762.6 997.7 966.1
Treatment-related TEAEs
Patients with at least one treatment-
related TEAE, n (%)
9 (42.9) 103 (73.6) 112 (69.6)
Rate, per 100 PY of exposure 227.2 290.0 281.5
TEAEs leading to discontinuation
Patients with at least one TEAE leading
to discontinuation, n (%)
3 (14.3) 15 (10.7) 18 (11.2)
Rate, per 100 PY of exposure 21.6 16.8 17.5
TESAEs
Patients with at least one TESAE, n (%) 3 (14.3) 7 (5.0) 10 (6.2)
Rate, per 100 PY of exposure 32.5 6.7 10.2
Serious infections
Patients with at least one event, n (%) 1 (4.8) 3 (2.1) 4 (2.5)
Rate, per 100 PY of exposure 10.8 2.5 3.6
TEAEs of special interestb
Patients with at least one TEAE of
special interest, n (%)
9 (42.9) 61 (43.6) 70 (43.5)
[95% CI 27.8, 66.0] [95% CI 35.2, 52.2] [95% CI 35.7, 51.5]
Deaths, n (%) 0 (0.0) 1 (0.7)c 1 (0.6)c
aIf a patient experienced more than one TEAE, the patient was counted once at the most intense or most related event.
bIdentified via SMQ.
cOwing to chronic pulmonary fibrosis. csDMARD: conventional synthetic DMARD; PY: patient-years; SMQ: standardized
Medical Dictionary for Regulatory Activities (MedDRA) query; TCZ-SC: tocilizumab s.c.; TEAE: treatment-emergent adverse
event; TESAE: treatment-emergent serious adverse event.
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Discussion
ACT-MOVE was a UK real-world study performed within
the TOZURA phase IV common-framework programme.
The primary objective was to assess the efficacy of
TCZ-SC, as monotherapy or in combination with
csDMARD(s), in patients with an inadequate response to
current csDMARD therapy or first TNF inhibitor, up to
week 52. Study findings showed that in a population of
patients with high mean disease activity at baseline,
TCZ-SC given alone or in combination with csDMARDs
led to mean decreases from baseline in DAS28-ESR
scores and an increase in the proportion of patients in
DAS28 clinical remission over the treatment period.
Other efficacy end-points, including CDAI, SDAI, ACR
response scores, EULAR response, tender joint count of
28 joints, swollen joint count of 28 joints and patient-
reported outcomes, also showed an improvement from
baseline over 52weeks with TCZ-SC alone or in combi-
nation. TCZ-SC was generally well tolerated as mono-
therapy and in combination, with safety data consistent
with the existing profile of TCZ-SC [14–16].
Outcomes in ACT-MOVE were generally comparable
to those from phase III trials of TCZ-IV, acknowledging
differences in patient populations and trial designs [5–9].
In a recent study of TCZ-IV plus MTX in patients with an
inadequate response to DMARDs, tapering MTX was
non-inferior to continuing stable MTX in terms of main-
taining a EULAR response in patients with a good/
moderate EULAR response at week 24. As observed in
ACT-MOVE, TCZ treatment was well tolerated and effi-
cacious in combination with csDMARDs [21]. Efficacy of
TCZ treatment in ACT-MOVE was similar whether as
monotherapy or with csDMARDs, concurring with a
meta-analysis of randomized controlled trials that com-
pared these two approaches [22]. ACT-MOVE efficacy
data were also comparable to those from the overall
TOZURA programme and other phase III trials of TCZ-
SC [14–16, 20], although the proportion of patients
achieving DAS28 clinical remission at week 24 was
higher in ACT-MOVE than in TOZURA for monotherapy
(73.7% ACT-MOVE, 59.0% TOZURA) and higher than in
the SUMMACTA study for combination therapy (65.0%
ACT-MOVE, 38.0% SUMMACTA) [14, 20]. ACR20 re-
sponse rate, the primary end-point in SUMMACTA, how-
ever, was comparable (71.4% ACT-MOVE, 69.4%
SUMMACTA).
In terms of safety, the rate of TEAEs in ACT-MOVE
per 100 PY was higher than the rate of AEs in the over-
all TOZURA programme (966.1 ACT-MOVE, 622.4
TOZURA), although the rate of TESAEs per 100 PY was
lower (10.2) than the rate of serious AEs in TOZURA
(14.6). In both studies, infections were the most com-
monly reported events; the rate of serious infections per
100 PY was 3.6 in both ACT-MOVE and TOZURA. With
reference to other specific TEAEs, cross-study compari-
sons across ACT-MOVE and TOZURA are difficult, be-
cause their frequency was reported as the number
(proportion) of patients affected, and the two studies
were of different durations (24 and 54weeks, respec-
tively). It is possible that the apparently higher rate of
non-serious AEs in ACT-MOVE might be related partly
to differences in study treatment; specifically, that a
slightly higher proportion of patients in this study re-
ceived combination treatment with TCZ-SC and a
csDMARD vs TCZ-SC monotherapy (ACT-MOVE: 87 vs
13%; TOZURA: 80 vs 20%). Any increase in AEs
reported here vs TOZURA is unlikely to reflect a need
for extra safety monitoring given that it appears related
to non-serious events only. Of note, the per 100 PY rate
of TESAEs in ACT-MOVE was lower than that of serious
AEs in a close to clinical practice study of TCZ-IV as
monotherapy or in combination with DMARDs (10.2 vs
20.1) [23]. Further comparisons with that TCZ-IV study
are, however, compromised by differences in study
length and AE data presentation. Overall, the ACT-
MOVE safety data reported here are generally reassuring
given that its real-world setting means patients are likely
to have more co-morbidities than those enrolled in
clinical trials. Co-morbidities were reported in 36% of
ACT-MOVE patients at baseline [most commonly, hyper-
tension (21%), hyperlipidaemia (8%), type 2 diabetes
(4%) and osteoporosis (4%)].
It is well established that biological therapies can elicit
the production of ADAs, which may negatively impact
treatment through reduced exposure/efficacy and trig-
gering of hypersensitivity reactions [24]. Consistent with
overall data from TOZURA [20], immunogenicity in ACT-
MOVE was infrequent in both monotherapy and combi-
nation groups.
The present findings from ACT-MOVE are similar to
those from a Spanish, retrospective, observational study
of switching from TCZ-IV to TCZ-SC in RA (DAS28 clini-
cal remission rates in that study were 75.5 and 87.3%
at weeks 24 and 52, respectively) [25]. Data from these
studies, alongside findings of TOZURA, provide a grow-
ing body of evidence showing that the efficacy and
safety of TCZ-SC in the real world are similar to obser-
vations during clinical development. However, the small
number of patients enrolled onto the TCZ-SC monother-
apy arm of ACT-MOVE limits the conclusions that can
be drawn specifically from this group. This small sample
size might account for the potential imbalance at base-
line between monotherapy and combination groups in
terms of glucocorticoid use and prior anti-TNF treat-
ment. Furthermore, the present study, and the overall
TOZURA programme, lacked a control arm and are sub-
ject to the limitations generally associated with real-
world studies, such as inclusion and expectation bias.
These limitations, however, are at least partly offset by
the benefits of including a broader, less selected patient
population. A novel aspect of our study vs the overall
TOZURA programme was assessment of MTX adher-
ence in patients prescribed MTX in combination with
TCZ-SC. At all time points, MTX adherence was >90%,
although the number of patients completing the adher-
ence questionnaire was relatively low at post-baseline
assessments.
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In summary, findings from ACT-MOVE demonstrate
the efficacy of TCZ-SC in patients with RA in a real-
world setting over a 1-year period. The efficacy of
TCZ-SC was similar whether it was prescribed as mono-
therapy or in combination with csDMARDs. The safety
profile was consistent with that previously established
for TCZ-SC.
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